Skip to main content
Clinical Trials/NCT05802069
NCT05802069
Recruiting
Not Applicable

Medical College of Wisconsin Master Predict (Profile Related Evidence Determining Individualized Cancer)

Sameem M. Abedin, MD1 site in 1 country10,000 target enrollmentDecember 19, 2022
ConditionsCancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cancer
Sponsor
Sameem M. Abedin, MD
Enrollment
10000
Locations
1
Primary Endpoint
Number of subjects receiving precision therapies providing biospecimens of any kind.
Status
Recruiting
Last Updated
8 months ago

Overview

Brief Summary

The study is an observational trial for patients undergoing cancer-related interventions and therapy at Medical College of Wisconsin Cancer Center. Projects under this protocol will use patient data that will be collected both retrospectively and prospectively. It will also enable prospective sample collection for specific cancer-related studies.

Detailed Description

This is a master protocol that enables investigators to conduct observational research and correlative biospecimen studies. This study is non-therapeutic, with retrospective and prospective components. This will be a single-site study at MCW/FH. Retrospective data and, with consent, prospective observational data will be collected. The study will also include an opportunity for patients to consent to the analysis of specimens collected prospectively during care and for the collection of research-related testing of blood, stool, and/or urine. It is designed to decrease the burden on both patients and investigators by allowing consent to a protocol that will enable multiple minimal-risk studies. Studies under this master protocol may perform data analysis using standard statistical techniques, as well as with advanced bioinformatics, machine learning, artificial intelligence, and other related technologies. Collection and testing of biospecimens will only be performed if a proposed study that falls under this master protocol requires it. Studies may include a variety of simple or advanced techniques related to chemical, hematologic, molecular, proteomic, transcriptomic, immunomic, and metabolic analyses, as well as related multi-omic analysis for biomarker discovery, understanding correlations between treatment and molecular features, and/or for pharmacokinetic (PK) and pharmacodynamic (PD) parameters.

Registry
clinicaltrials.gov
Start Date
December 19, 2022
End Date
December 1, 2027
Last Updated
8 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Sameem M. Abedin, MD
Responsible Party
Sponsor Investigator
Principal Investigator

Sameem M. Abedin, MD

Assistant Professor

Medical College of Wisconsin

Eligibility Criteria

Inclusion Criteria

  • Subjects aged 18 years and older who were previously or are currently receiving care for a cancer-related condition at MCW/FH.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Number of subjects receiving precision therapies providing biospecimens of any kind.

Time Frame: One year

Precision therapies are targeted against specific genomic mutations.

Number of subjects not receiving precision therapies and providing biospecimens.

Time Frame: One year

Precision therapies are targeted against specific genomic mutations.

Study Sites (1)

Loading locations...

Similar Trials